These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis. Kim S; Kim HT; Suh HS J Dermatolog Treat; 2018 May; 29(3):314-321. PubMed ID: 28504036 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors. Bafaloukos D; Papaxoinis G; Linardou H; Diamantopoulos P; Laskarakis A; Anastasopoulou A; Sergentanis TN; Tarampikou A; Tsoutsos D; Gogas H Melanoma Res; 2019 Aug; 29(4):428-434. PubMed ID: 30601377 [TBL] [Abstract][Full Text] [Related]
10. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma. Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703 [TBL] [Abstract][Full Text] [Related]
11. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. Puzanov I; Ribas A; Robert C; Schachter J; Nyakas M; Daud A; Arance A; Carlino MS; O'Day SJ; Long GV; Margolin KA; Dummer R; Schadendorf D; Lutzky J; Ascierto PA; Tarhini A; Lin J; Mogg R; Homet Moreno B; Ibrahim N; Hamid O JAMA Oncol; 2020 Aug; 6(8):1256-1264. PubMed ID: 32672795 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. Pires da Silva I; Zakria D; Ahmed T; Trojanello C; Dimitriou F; Allayous C; Gerard C; Zimmer L; Lo S; Michielin O; Lebbe C; Mangana J; Ascierto PA; Johnson DB; Carlino M; Menzies A; Long G J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798536 [TBL] [Abstract][Full Text] [Related]
14. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644 [TBL] [Abstract][Full Text] [Related]
15. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. Johnson DB; Flaherty KT; Weber JS; Infante JR; Kim KB; Kefford RF; Hamid O; Schuchter L; Cebon J; Sharfman WH; McWilliams RR; Sznol M; Lawrence DP; Gibney GT; Burris HA; Falchook GS; Algazi A; Lewis K; Long GV; Patel K; Ibrahim N; Sun P; Little S; Cunningham E; Sosman JA; Daud A; Gonzalez R J Clin Oncol; 2014 Nov; 32(33):3697-704. PubMed ID: 25287827 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of total metabolic tumour volume and therapy-response assessment by [ Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873 [TBL] [Abstract][Full Text] [Related]
17. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064 [TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data. Czirbesz K; Gorka E; Balatoni T; Pánczél G; Melegh K; Kovács P; Gézsi A; Liszkay G Pathol Oncol Res; 2019 Jan; 25(1):45-50. PubMed ID: 28963614 [TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. Goodman RS; Di Guardo L; Maurichi A; Kirwin B; Khattak A; Vanella V; Lee J; Lawless A; Czapla J; Spagnoletti A; Ambrosini M; Livingstone E; Long GV; Sullivan RJ; Carlino MS; Atkinson V; Trojanello C; Ascierto PA; Schadendorf D; Warburton L; Menzies AM; Santinami M; Johnson DB Eur J Cancer; 2023 Nov; 194():113354. PubMed ID: 37827067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]